ArticleGlobal medical genetics2025
Characterization of stem cell landscape and identification of stemness-related gene ENY2 in colorectal cancer by intergrated transcriptomic analysis.
Article in Global medical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer stem cells (CSCs) drive colorectal cancer (CRC) progression, metastasis, and therapy resistance, but their heterogeneity limits targeted treatment efficacy. Clarifying the stemness landscape and underlying mechanisms is crucial for developing effective CRC therapies. Methods: By integrating 10 ×single-cell data from GSE201348 and GSE161277, we constructed a single-cell atlas of nine primary CRC samples. CSCs were identified via scRNA-seq analyses. Using integrative bioinformatics tools, we identified ENY2 as a stemness-related marker and explored its potential role in CRC. We further compared genetic variants, immune infiltration, and drug sensitivity between high and low ENY2 expression groups. Results: Stem cell clusters (M0 and M7) in CRC were identified based on copy number variation, pseudotime trajectory, and CytoTRACE analyses. By integrating marker gene profiles, DEGs from GSE33113, CytoTRACE-based CSC genes, and prognostic genes from GSE17536, we identified two key stemness-related markers: ENY2 and PKM. ENY2 was prioritized for further analysis due to its limited investigation in CRC. Bioinformatic analyses revealed that ENY2 was significantly upregulated and associated with poor prognosis. Enrichment analyses indicated its involvement in MYC and E2F targets, G2M checkpoint, and EMT pathways. Drug sensitivity prediction suggested that high ENY2 expression may confer responsiveness to 5-fluorouracil, capecitabine, oxaliplatin, and 24 other potential agents. Conclusions: ENY2 may act as a key CSC-associated biomarker that promotes CRC tumorigenesis and metastasis via the EMT pathway, which enhance our understanding of CRC pathogenesis and highlight ENY2 as a potential target for diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.